These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 30118516)

  • 1. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.
    Lee CH; Jung JH; Son SH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
    PLoS One; 2018; 13(8):e0202644. PubMed ID: 30118516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma.
    Keshavarzi A; Alaei-Shahmiri F; Fallahi B; Emami Z; Malek M; Khamseh ME
    BMC Endocr Disord; 2024 Jul; 24(1):112. PubMed ID: 39004697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.
    Robenshtok E; Grewal RK; Fish S; Sabra M; Tuttle RM
    Thyroid; 2013 Apr; 23(4):436-42. PubMed ID: 23067402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
    Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer.
    Kwon SY; Kim J; Jung SH; Chong A; Song HC; Bom HS; Min JJ
    Clin Nucl Med; 2016 Jan; 41(1):e32-8. PubMed ID: 26164179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
    Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
    Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
    Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer.
    Jia X; Wang Y; Yang L; Fan K; Tao R; Liu H; Yao X; Yang A; Zhang G; Gao R
    Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
    Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
    Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of thyroglobulin in the lymph nodes recurrence of papillary thyroid carcinoma undergoing total thyroidectomy.
    Xing Z; Qiu Y; Li Z; Zhang L; Fei Y; Zhu J; Su A
    BMC Surg; 2021 Jan; 21(1):53. PubMed ID: 33482804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
    Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
    Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is postablation whole-body
    Liu B; Chen Y; Jiang L; He Y; Huang R; Kuang A
    Clin Endocrinol (Oxf); 2017 Jan; 86(1):134-140. PubMed ID: 27434740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.